Hydroxyzine Drug Test Guide: Panels, Detection Windows & More
Evidence-based answer reviewed against SAMHSA cutoffs and FDA assay documentation · Updated August 2026
Quick answer: First-gen antihistamine anxiolytic — partially covered on the federal 5-panel. Urine detects it roughly interference ~1–3 days post-dose; hair archives ~90 days; saliva and blood track only recent use. Not screened; TCA-strip cross-reactivity risk.
Overview
This guide covers everything verifiable about how testing handles Hydroxyzine (hydroxyzine/hydroxyzine) (also searched as: hydroxyzine, hydroxyzine): which panels include it, detection windows across specimens, cutoff levels, false-positive risks, and legitimate prescription handling.
Panel membership
| Panel | Hydroxyzine status |
|---|---|
| 5-Panel | ⚠️ Screen interference only |
| 10-Panel | ⚠️ Screen interference only |
| 12-Panel | ⚠️ Screen interference only |
| DOT 5-panel (safety-sensitive) | ❌ Not included |
Detection windows
| Test type | Typical Hydroxyzine detection window |
|---|---|
| Urine | any: interference ~1–3 days post-dose |
| Saliva (Mouth Swab) | any: n/a |
| Hair Follicles | n/a |
| Blood | any: n/a |
Cutoff levels
Not screened; TCA-strip cross-reactivity risk.
Cutoffs exist to separate real use from noise — dietary exposure, passive contact and legacy medications stay below them by design. Screen-above-cutoff results still require mass-spec confirmation before reporting.
Deep-dive facts
Hydroxyzine is never a target analyte. Structurally antihistamine-TCA adjacent, it can flag tricyclic screens (like diphenhydramine). Confirmations close the loop.
False positives & cross-reactivity
- TCA-screen cross-reactivity (assay-dependent).
| Screen flagged | Documented cross-reactants (immunoassay tier only) |
|---|---|
| Amphetamines | Bupropion (bupropion), trazodone, phentermine, pseudoephedrine, labetalol, promethazine, methylphenidate |
| PCP | Dextromethorphan (dextromethorphan cough syrup), diphenhydramine (diphenhydramine), doxylamine (multi-symptom cold remedies), tramadol, venlafaxine (venlafaxine), ketamine |
| Opiates | Poppy seeds (true positive), quinine, dextromethorphan, ofloxacin/levofloxacin, rifampin |
| Benzodiazepines | Sertraline (sertraline), oxaprozin (case reports) |
| Methadone | Diphenhydramine, doxylamine, verapamil, quetiapine (quetiapine), clomipramine |
| Tricyclics (TCA) | Cyclobenzaprine (cyclobenzaprine), hydroxyzine, carbamazepine, diphenhydramine |
| Cannabinoids (THC) | Efavirenz, pantoprazole (isolated reports); dronabinol/dronabinol = true positive |
Legal status note
Prescription only, unscheduled.
Popular guides in this series
Certified labs nationwide · Results in 1–2 days
Need a test? Order online, test same-day →People also ask
Does Hydroxyzine Show up on a Drug Test?
Yes — Hydroxyzine appears on standard drug panels. Full guide →
Can Hydroxyzine Cause a False Positive Drug Test?
Can Hydroxyzine trigger a false positive? Cross-reactivity evidence, confirmation testing, and how to clear your name with the MRO. Full guide →
Hydroxyzine Drug Test Guide: Panels, Detection Windows & More?
Complete Hydroxyzine drug test guide: which panels detect it, urine/hair/saliva/blood detection windows, cutoff levels and prescription verification. Full guide →
How Long Does Hydroxyzine Stay in Urine?
How long Hydroxyzine stays detectable in urine — urine, hair, saliva & blood windows explained with cutoffs. Full guide →
How accurate are drug tests?
Lab-based immunoassay screens agree with confirmation testing ~97% of the time; confirmed GC–MS results are considered definitive. Home kits trade legal defensibility for convenience.
Do prescriptions count against me?
No — verified prescriptions report as negative through the Medical Review Officer. Declare medications at collection and answer the follow-up call.
Sources & further reading
- SAMHSA — Mandatory Guidelines for Federal Workplace Drug Testing Programs (cutoffs, MRO process)
- DOT — 49 CFR Part 40 procedures for transportation workplace testing
- Brahm NC et al., Mayo Clinic Proceedings 2008;83(1):66–76 — false-positive cross-reactivity reference
- FDA — drug-of-abuse test device labeling (detection window conventions)